Banerjee Mustafi Soumyajit, Chakraborty Prabir Kumar, Naz Sarwat, Dwivedi Shailendra Kumar Dhar, Street Mark, Basak Rumki, Yang Da, Ding Kai, Mukherjee Priyabrata, Bhattacharya Resham
Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; Department of Obstetrics and Gynecology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA.
Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, OK, USA; Department of Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA.
Biochim Biophys Acta. 2016 Aug;1859(8):983-93. doi: 10.1016/j.bbagrm.2016.06.002. Epub 2016 Jun 22.
Chemotherapy-induced emergence of drug resistant cells is frequently observed and is exemplified by the expression of family of drug resistance proteins including, multidrug resistance protein 1 (MDR1). However, a concise mechanism for chemotherapy-induced MDR1 expression is unclear. Mechanistically, mutational selection, epigenetic alteration, activation of the Wnt pathway or impaired p53 function have been implicated. The present study describes that the surviving fraction of cisplatin resistant cells co- upregulate MDR1, BMI1 and acetyl transferase activity of TIP60. Using complementary gain and loss of function approaches, we demonstrate that the expression of MDR1 is positively regulated by BMI1, a stem-cell factor classically known as a transcriptional repressor. Our study establishes a functional interaction between TIP60 and BMI-1 resulting in upregulation of MDR1 expression. Chromatin immunoprecipitation (ChIP) assays further establish that the proximal MDR1 promoter responds to cisplatin in a BMI1 dependent manner. BMI1 interacts with a cluster of E-box elements on the MDR1 promoter and recruits TIP60 resulting in acetylation of histone H2A and H3. Collectively, our data establish a hitherto unknown liaison among MDR1, BMI1 and TIP60 and provide mechanistic insights into cisplatin-induced MDR1 expression resulting in acquired cross-resistance against paclitaxel, doxorubicin and likely other drugs. In conclusion, our results advocate utilizing anti-BMI1 strategies to alleviate acquired resistance to chemotherapy.
化疗诱导的耐药细胞出现屡见不鲜,多药耐药蛋白1(MDR1)等耐药蛋白家族的表达即为例证。然而,化疗诱导MDR1表达的具体机制尚不清楚。从机制上讲,涉及突变选择、表观遗传改变、Wnt通路激活或p53功能受损。本研究表明,顺铂耐药细胞的存活部分共同上调MDR1、BMI1和TIP60的乙酰转移酶活性。我们采用功能获得和功能缺失的互补方法,证明MDR1的表达受BMI1正向调控,BMI1是一种经典的转录抑制因子,属于干细胞因子。我们的研究确立了TIP60与BMI-1之间的功能相互作用,导致MDR1表达上调。染色质免疫沉淀(ChIP)分析进一步证实,MDR1启动子近端以BMI1依赖的方式对顺铂作出反应。BMI1与MDR1启动子上的一组E盒元件相互作用,并募集TIP60,导致组蛋白H2A和H3乙酰化。总体而言,我们的数据在MDR1、BMI1和TIP60之间建立了一种前所未知的联系,并为顺铂诱导的MDR1表达提供了机制性见解,这种表达导致对紫杉醇、阿霉素以及可能其他药物产生获得性交叉耐药。总之,我们的结果主张采用抗BMI1策略来减轻化疗获得性耐药。